Hikma Pharmaceuticals PLC 2018 AR2
The report highlights Hikma's strong financial and operational performance in 2018, with Group revenue increasing by 7% to $2.07 billion and core operating profit rising by 19% to $460 million. The company successfully transitioned to a new leadership structure with the appointment of its first non-family CEO, Sigurdur Olafsson. In sustainability, Hikma maintained its membership in the FTSE4Good Index, increasing its score to 3.5 out of 5. The company also expanded its community impact through a global partnership with Direct Relief and became a Patron of The Prince's Trust, while continuing to address drug shortages and anti-microbial resistance.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2018
Type: AR2
Pages: 180
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma's strong financial and operational performance in 2018, with Group revenue increasing by 7% to $2.07 billion and core operating profit rising by 19% to $460 million. The company successfully transitioned to a new leadership structure with the appointment of its first non-family CEO, Sigurdur Olafsson. In sustainability, Hikma maintained its membership in the FTSE4Good Index, increasing its score to 3.5 out of 5. The company also expanded its community impact through a global partnership with Direct Relief and became a Patron of The Prince's Trust, while continuing to address drug shortages and anti-microbial resistance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women on Board
Women in Management
Employees